The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

ABSTRACT: Imatinib mesylate was the first tyrosine kinase inhibitor (TKI) approved for the management of chronic myeloid leukemia. Imatinib produces acceptable responses in approximately 60% of patients, with approximately 20% discontinuing therapy because of intolerance and approximately 20% developing drug resistance. The advent of newer TKIs, such as nilotinib, dasatinib, bosutinib, and ponatinib, has provided multiple options for patients. These agents are more potent, have unique adverse effect profiles, and are more likely to achieve relevant milestones, such as early molecular responses (3-6 months) and optimal molecular responses (12 months). The acquisition of BCR-ABL kinase domain mutations is also reportedly lower with these drugs. Thus far, none of the randomized phase III clinical trial

SUBMITTER: Pophali PA 

PROVIDER: S-EPMC4742366 | biostudies-literature | 2016 Jan-Feb

REPOSITORIES: biostudies-literature